Considering Assisted Reproduction Abroad After 40: How Do AMH Levels and Antral Follicle Count Affect Treatment Decisions?

When women of advanced maternal age consider assisted reproductive treatment abroad, their first question is often: Are my AMH level and antral follicle count sufficient to justify another egg retrieval cycle?

These two indicators can influence the intensity of ovarian stimulation and help determine whether continued treatment with a woman’s own eggs remains reasonable or whether donor eggs and other alternatives should also be considered. This article explains how ovarian reserve is interpreted across different age groups and why the same AMH result may lead to different recommendations at different fertility centers.

AMH and Antral Follicle Count Reflect Quantity, Not the Final Outcome

Anti-Müllerian hormone, or AMH, is mainly used to estimate the pool of follicles that may respond to ovarian stimulation. Antral follicle count, or AFC, is generally measured by transvaginal ultrasound during the early follicular phase and includes small follicles in both ovaries, commonly measuring approximately 2–10 millimeters.

Both indicators are useful for estimating ovarian response and the possible number of eggs retrieved. However, neither can independently determine egg quality, embryo chromosomal status or the likelihood of achieving a live birth.

The American Society for Reproductive Medicine states that AMH and AFC are useful predictors of ovarian response and egg yield, while age remains a stronger predictor of reproductive outcome. An extremely low AMH level should not, by itself, be used as a reason to deny IVF treatment.

For this reason, an AMH level of 0.8 ng/mL does not have the same meaning for a 34-year-old woman as it does for a 42-year-old woman. The younger patient may mainly face the problem of retrieving fewer eggs and may still have a reasonable opportunity to accumulate embryos over one or more cycles. The older patient must consider both limited egg numbers and the age-related increase in chromosomal abnormalities, as well as the time required for repeated retrievals.

The Value of Using One’s Own Eggs Depends on Four Groups of Information

A meaningful assessment cannot be based on a single AMH report. Doctors usually review the following information together:

• Age, menstrual regularity and previous pregnancies;

• AFC, FSH and estradiol measured during the early follicular phase;

• Previous stimulation dosage, number of mature eggs, fertilization rate and blastocyst development;

• Uterine condition, semen analysis and genetic risks affecting either partner.

If AMH is low but several antral follicles remain visible, and previous cycles have produced mature eggs or blastocysts, another attempt with the patient’s own eggs may still be medically reasonable.

In contrast, if several consecutive cycles produce very few mature eggs or repeatedly fail to generate usable embryos, the patient should reconsider the balance between further retrievals, embryo accumulation and donor egg treatment.

There is no universal definition of an “acceptable” number of retrieved eggs. A younger woman may still obtain a viable embryo from a small number of eggs. After age 40, the same egg yield may require several cycles to improve the chance of obtaining a chromosomally suitable embryo.

Why Fertility Centers May Recommend Different Strategies

Different recommendations do not necessarily mean that one clinic is right and another is wrong. Clinics may be working toward different treatment objectives.

Some centers aim to recruit as many follicles as possible in a single cycle. Others prefer mild stimulation and consecutive retrievals. Some clinics recommend blastocyst culture, preimplantation genetic testing or donor eggs at an earlier stage.

The proposed strategy may also be influenced by the clinic’s experience with poor responders, embryology laboratory capability, local regulations and the amount of time an international patient can remain in the destination.

Patients should therefore ask for clear answers to five questions:

1. How many follicles are expected to respond?

2. What is the risk of cycle cancellation or retrieving no mature eggs?

3. Should embryos be accumulated over several cycles?

4. Is PGT appropriate when only a small number of embryos are available?

5. After how many unsuccessful attempts should the strategy be reassessed?

Hong Kong Can Serve as an Assessment Base, but Its Legal Boundaries Are Strict

Hong Kong has established reproductive medicine, genetic counseling and laboratory services. It may be suitable for reviewing ovarian reserve, obtaining a second medical opinion and discussing ovarian stimulation or embryo-related strategies.

However, reproductive technology and third-party reproductive arrangements are strictly regulated in Hong Kong. Commercial surrogacy is prohibited. Payments for commercial surrogacy arrangements are not permitted, and surrogacy agreements are not legally enforceable. Additional requirements apply to marital status, gamete sources and applications for parental orders after birth.

Hong Kong may therefore function as a location for examinations, clinical assessment and treatment planning. A medical opinion obtained in Hong Kong should not be interpreted as confirmation that every overseas third-party reproductive arrangement is legally available.

Overseas Treatment Should Be Divided into Three Decisions

For women of advanced maternal age, Thailand, Georgia and Kyrgyzstan should not be compared only by price. The decision should be separated into three practical questions.

1. Where Should Egg Retrieval and Embryo Culture Be Completed?

Thailand has a relatively mature international medical sector and established assisted reproduction laboratories. It may appeal to patients who value convenient travel within Asia, structured ovarian stimulation and embryology services.

However, the ability to undergo IVF in Thailand does not automatically mean that foreign patients can legally enter a surrogacy arrangement there. Commercial surrogacy remains prohibited, and access for foreign intended parents is restricted. Current eligibility must be verified before treatment.

Georgia and Kyrgyzstan offer different forms of cross-border assisted reproductive care. Before starting treatment, patients should verify the clinic’s licence, eligibility requirements, marital-status rules, permitted gamete sources, contractual parties and procedures for birth documentation.

Foreign nationals, single intended parents and families using donated gametes should obtain separate written reviews from a licensed medical provider and a qualified local lawyer.

2. Should Eggs or Embryos Be Accumulated?

For women who have a low AFC but still wish to use their own eggs, consecutive cycles may be considered to accumulate mature eggs or blastocysts before deciding whether to proceed with genetic testing and transfer.

Whether accumulation is worthwhile depends on age, mature egg yield, blastocyst formation rate and the number of cycles the patient is medically, financially and emotionally prepared to undergo. It should not be based on a fixed target number applied to every patient.

3. Should an Alternative Path Be Prepared at the Same Time?

Preparing an alternative does not mean immediately abandoning treatment with one’s own eggs.

A more practical strategy may be to continue a medically reasonable self-egg attempt while also learning about donor eggs, embryo transfer and other legally available options. If consecutive cycles perform below expectations, the next plan can begin without repeating the entire information-gathering process.

A Useful Assessment Should Produce Three Conclusions

A proper international fertility consultation should provide more than a simple answer of “yes” or “no.” It should clarify:

• The medical value of continuing with the patient’s own eggs and a suggested limit on retrieval attempts;

• The approximate number of eggs and embryos that may be expected from each cycle;

• The alternative plan to consider if the actual response is lower than expected.

Advanced maternal age is not an absolute contraindication to assisted reproductive treatment abroad, but every decision should begin with an accurate ovarian reserve assessment.

Expectations regarding an acceptable egg yield differ by age. Pursuing treatment with one’s own eggs without a defined reassessment point may prolong the overall process. If you already have recent AMH and AFC reports, an initial assessment can help determine whether it is more reasonable to continue with your own eggs, modify the stimulation strategy or explore other available options in parallel.

The objective is not simply to complete another cycle, but to make a balanced decision between time, physical burden and the realistic probability of obtaining a usable embryo.